ClinicalTrials.gg
Active, not recruitingNCT06468033Updated Aug 13, 2026

P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk

A Phase 3 interventional study of Ropeginterferon alfa-2b and Placebo in Primary Myelofibrosis and Myeloproliferative Neoplasm, sponsored by PharmaEssentia. Active, not recruiting at 73 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by PharmaEssentia · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Primary Myelofibrosis with a site in China — 13 open to participants now, 22 under way, 4 of them phase 3. Primary Myelofibrosis · China.

Enrollment
10th of 35
160 · median 87
Started
2025
with 2 others
Phase 3
8 of 41
1 open now
Primary completion
2027-11
later than 12 of 21 live
Registered
28th of 41
by date

Among the 41 studies in Primary Myelofibrosis with a site in China, this one is the 10th largest by enrollment of the 35 interventional ones that give a count, is one of 3 that started in 2025, is one of 8 in phase 3, reaches primary completion later than 12 of the 21 other live ones, and was the 28th registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

13 of the 41 studies in Primary Myelofibrosis with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Primary Myelofibrosis with a site in China, or all of them as a file.
02

Study summary

This is a phase 3 double-blind clinical trial arm to test Ropeginterferon alfa-2b (P1101) in adult patients with Primary Myelofibrosis (PMF) at early stage or low to medium risk.

Participants will receive the study drug/placebo bi-weekly and have an assessment visit every 4 weeks. The ratio of study drug to placebo group is 2:1.

03

Conditions studied

  • Primary Myelofibrosis
  • Myeloproliferative Neoplasm

Keywords

  • P1101
  • Primary Myelofibrosis
  • PMF
  • Ropeginterferon
  • PharmaEssentia
  • Myeloproliferative neoplasms
  • MPN
  • Pre-fibrotic
  • Low or Intermediate-1 Risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged ≥18 years at the time of signing the form;
  2. Patients with pre-fibrotic/early PMF (Pre-PMF) or overt primary myelofibrosis at low to intermediate-1 risk according to DIPSS plus, diagnosed according to WHO 2016 or 2022 classification;
  3. With good liver function at screening, which is defined as total ≤1.5 × (ULN), (INR) ≤1.5 × ULN, albumin >3.5 g/dL, (ALT) ≤2.0 × ULN, and aspartate aminotransferase (AST) ≤2.0 × ULN;
  4. ≥10.0 g/dL at screening;
  5. ≥1.0 × 10\^9/L at screening;
  6. rate ≥30 mL/min at screening (according to the Cockcroft-Gault formula);
  7. Females of , as well as all women \<2 years after the onset of menopause, must agree to use an acceptable form of until 60 days following the last dose of the study drug, and females must agree to not breastfeed during the study;
  8. Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Any known to interferon α or to interferon α;
  2. Patients with prior interferon therapy having poor tolerability or lack of efficacy to the previous interferon therapy per investigator\'s judgement;
  3. Patients with an ongoing cytoreduction (e.g., HU or IFN-α) at the time of screening if, in the Investigator's opinion, randomizing them into the placebo arm will lead to immediate rebound increase of peripheral blood counts and thus may jeopardize their health status;
  4. With severe or serious diseases that, in the Investigator's opinion, may affect the patient's participation in this study;
  5. History of major organ transplantation;
  6. Pregnant or breastfeeding women;
  7. Patients with any other diseases that will affect the study results or may weaken the compliance to protocol per the Investigator's judgment;
  8. Use any drug \<4 weeks prior to the first dose of study drug, or not recovered from effects of prior administration of any investigational drug.
  9. Eligible for JAK inhibitor therapy at screening.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    Ropeginterferon alfa-2b (P1101)

    Ropeginterferon alfa-2b (P1101) is administrated subcutaneously (SC) every two weeks (± 3 days) until 80 weeks.

    Biological: Ropeginterferon alfa-2b

  • Placebo comparator
    Placebo control

    Placebo is administrated subcutaneously (SC) every two weeks (± 3 days) until 80 weeks.

    Other: Placebo

Interventions

  • Pre-filled Syringe. Dosage: up to 500mcg

    Also known as: P1101

  • OtherPlacebo

    Placebo is a look-alike substance with the intervention (Ropeginterferon alfa-2b) that contains no active drug.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Platelet count equal or less (≤) 400 × 10^9/L

    Platelet count ≤400 × 10\^9/L is one of the criteria for clinically relevant complete hematologic response (CrCHR).

    Time frame: 80 weeks

  2. Number of Participants with White Blood Cells (WBC) count equal or less (≤) 10 × 10^9/L

    White Blood Cells (WBC) count ≤10 × 10\^9/L is one of the criteria for clinically relevant complete hematologic response (CrCHR).

    Time frame: 80 weeks

  3. Number of Participants with Hemoglobin (Hgb) equal or greater (≧) 10.0 g/dL

    Peripheral blood: Hemoglobin (Hgb) ≧ 10.0 g/dL is one of the criteria for clinically relevant complete hematologic response (CrCHR).

    Time frame: 80 weeks

  4. Number of Participants absence of major thrombotic events

    The absence of major thrombotic events during the observation time frame is one of the criteria for clinically relevant complete hematologic response (CrCHR).

    Time frame: 80 weeks

  5. Number of Participants with no progression to secondary acute myeloid leukemia (AML).

    The absence of progression to secondary acute myeloid leukemia (AML) is one of the criteria for clinically relevant complete hematologic remission (CrCHR).

    Time frame: 80 weeks

  6. Number of Participants with no progression on the Total Symptom Score (TSS)

    The TSS score is utilized to evaluate clinical symptoms, which is based on the MFSAF Total Symptom Score (TSS) form v4.0. No progression is defined as: * The participants who still have a TSS score equal to or less than (≤) 10 If the baseline score is ≤ 10. * The participants with a TSS score no increase than 50% If the baseline score is greater than (\&amp;amp;gt;) 10.

    Time frame: 80 weeks

07

Study locations

73 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2027, 28 months after the start.

Of 22 phase 3 interventional studies under Primary Myelofibrosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 68. This study's planned 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 21, 2024
StartActual
Jul 18, 2025
Primary completionEst.
Nov 18, 2027
CompletionEst.
Jan 11, 2029
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06468033
Lead sponsor
PharmaEssentia
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jul 18, 2025
Primary completion
Nov 18, 2027 (estimated)
Completion
Jan 11, 2029 (estimated)
Last update
Aug 13, 2026

Study contacts

Toshiaki Sato, MD/PhD
study director · PharmaEssentia JP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropeginterferon alfa-2b

Start the discussion